JP6216921B2 - アルファ−１抗トリプシン融合分子のための組成物、方法および使用 - Google Patents

アルファ−１抗トリプシン融合分子のための組成物、方法および使用 Download PDF

Info

Publication number
JP6216921B2
JP6216921B2 JP2014517226A JP2014517226A JP6216921B2 JP 6216921 B2 JP6216921 B2 JP 6216921B2 JP 2014517226 A JP2014517226 A JP 2014517226A JP 2014517226 A JP2014517226 A JP 2014517226A JP 6216921 B2 JP6216921 B2 JP 6216921B2
Authority
JP
Japan
Prior art keywords
aat
composition
subject
administration
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014517226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519852A5 (OSRAM
JP2014519852A (ja
Inventor
チャールズ エー． ディナレロ，
チャールズ エー． ディナレロ，
ソヒュン キム，
ソヒュン キム，
ジェイムズ ディー． クラポ，
ジェイムズ ディー． クラポ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2014519852A publication Critical patent/JP2014519852A/ja
Publication of JP2014519852A5 publication Critical patent/JP2014519852A5/ja
Application granted granted Critical
Publication of JP6216921B2 publication Critical patent/JP6216921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
JP2014517226A 2011-06-24 2012-06-22 アルファ−１抗トリプシン融合分子のための組成物、方法および使用 Expired - Fee Related JP6216921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500795P 2011-06-24 2011-06-24
US61/500,795 2011-06-24
PCT/US2012/043869 WO2012178102A2 (en) 2011-06-24 2012-06-22 Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016246746A Division JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Publications (3)

Publication Number Publication Date
JP2014519852A JP2014519852A (ja) 2014-08-21
JP2014519852A5 JP2014519852A5 (OSRAM) 2015-08-06
JP6216921B2 true JP6216921B2 (ja) 2017-11-01

Family

ID=47423247

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014517226A Expired - Fee Related JP6216921B2 (ja) 2011-06-24 2012-06-22 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2016246746A Withdrawn JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2019012303A Pending JP2019058197A (ja) 2011-06-24 2019-01-28 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2020120557A Pending JP2020171316A (ja) 2011-06-24 2020-07-14 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016246746A Withdrawn JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2019012303A Pending JP2019058197A (ja) 2011-06-24 2019-01-28 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2020120557A Pending JP2020171316A (ja) 2011-06-24 2020-07-14 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Country Status (7)

Country Link
US (5) US9938353B2 (OSRAM)
EP (2) EP2723370A4 (OSRAM)
JP (4) JP6216921B2 (OSRAM)
KR (2) KR20200044138A (OSRAM)
AU (4) AU2012272636A1 (OSRAM)
CA (1) CA2839917A1 (OSRAM)
WO (1) WO2012178102A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017079769A (ja) * 2011-06-24 2017-05-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504144A (ja) 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PT2726092T (pt) * 2011-06-28 2019-10-08 Lp Inhibrx Polipéptidos de fusão serpina e métodos para a sua utilização
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2014160768A1 (en) 2013-03-29 2014-10-02 The Regents Of The University Of Colorado Compositions and methods for preparing a subject for organ or non-organ implantation
CN105431165A (zh) * 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
ES2913946T3 (es) 2013-07-08 2022-06-06 The Univ Of Utah Research Foundation Péptido y su uso en el tratamiento de trastornos inflamatorios
WO2015140970A1 (ja) * 2014-03-19 2015-09-24 株式会社安川電機 回転電機及び回転電機の製造方法
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
WO2016144984A1 (en) * 2015-03-10 2016-09-15 Anvil Biosciences, Llc Serpins for the treatment of neuroinflammatory diseases
EP3585423A4 (en) * 2017-02-21 2020-12-23 Kamada Ltd. METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR EARLY INTERVENTION IN PULMONARY DISEASES
PT3716998T (pt) * 2017-12-01 2024-04-09 Csl Behring Llc A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION WITH A FUSION PROTEIN AND THEIR USE
CN109251936B (zh) * 2018-09-20 2021-09-10 四川理工学院 一种光滑鳖甲丝氨酸蛋白酶抑制剂融合蛋白及制备与应用
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
IL294959A (en) * 2020-01-30 2022-09-01 Vertex Pharma Methods of treatment for alpha-1 antitrypsin deficiency
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity
KR102689456B1 (ko) * 2020-11-16 2024-07-29 경북대학교 산학협력단 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물
WO2023198757A1 (en) * 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
WO2024261171A1 (en) * 2023-06-22 2024-12-26 Aatec Medical Gmbh Recombinant aat from yeast to treat transplants
EP4480493A1 (en) * 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung
WO2025014986A2 (en) * 2023-07-10 2025-01-16 Precigen, Inc. Therapy for alpha-1 antitrypsin deficiency
KR20250076724A (ko) * 2023-11-22 2025-05-30 아주대학교산학협력단 지속형 재조합 알파-1 항트립신 및 이의 용도

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GB1472700A (en) 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
JPS5470241A (en) 1977-11-09 1979-06-05 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
GB2044760B (en) 1979-03-01 1983-03-23 Ono Pharmaceutical Co Guanidinobenzoic acid derivatives
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US4629567A (en) 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US5157019A (en) 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4829054A (en) 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
US4857538A (en) 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4963654A (en) 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
JP2568281B2 (ja) 1989-11-17 1996-12-25 原田工業株式会社 自動車用三波共用アンテナ
US5714140A (en) 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
EP0512090B2 (en) 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Treatment of inflammation
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
WO1992018141A1 (en) 1991-04-18 1992-10-29 The Uab Research Foundation Compositions and methods for inhibiting elastase
US5175253A (en) 1991-04-24 1992-12-29 Washington University Binding peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
WO1993018794A1 (en) 1992-03-26 1993-09-30 Gensia, Inc. In vivo peptide therapy
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5604201A (en) 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5346886A (en) 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
JPH0827371A (ja) 1994-05-09 1996-01-30 Japan Carlit Co Ltd:The 紫外線及び赤外線吸収樹脂組成物
AU2790895A (en) 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5514653A (en) 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5712117A (en) 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
WO1997024339A1 (en) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
AU734615B2 (en) 1996-12-06 2001-06-21 Cortech, Inc. Serine protease inhibitors
US6150332A (en) 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
US6127145A (en) 1997-02-13 2000-10-03 Applied Phytologics, Inc. Production of α1 -antitrypsin in plants
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6124257A (en) 1997-08-28 2000-09-26 Lezdey; John Method of treatment
US6964869B2 (en) 1998-07-13 2005-11-15 Wisconsin Alumni Research Foundation Method and composition for skin grafts
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
EP1150699A4 (en) 1999-02-01 2004-06-30 John Lezdey TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS
GB9904421D0 (en) 1999-02-25 1999-04-21 Univ Edinburgh Telecommunications receiver
JP2002537810A (ja) * 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
WO2000051625A1 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000052034A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6174859B1 (en) 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
AU1101501A (en) 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors
JP2003515325A (ja) 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
US6955845B1 (en) 2000-06-30 2005-10-18 Owens Corning Fiberglas Technology, Inc. Acoustical and thermal insulator
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
IL156770A0 (en) 2001-01-04 2004-02-08 Vascular Biogenics Ltd Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
ES2370235T3 (es) 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2002094986A2 (en) 2001-05-21 2002-11-28 Board Of Reagents Next-nearest-neighbor sequence determinants of antisense dna
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
JP2005508141A (ja) 2001-05-25 2005-03-31 セローノ ジェネティクス インスティテュート ソシエテ アニニム ヒトｃＤＮＡおよびタンパク質、ならびにそれらの使用
US7001884B2 (en) 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease
EP1401867A2 (en) 2001-06-22 2004-03-31 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
MXPA04006053A (es) 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
WO2003068934A2 (en) 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
DE60333937D1 (de) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
AU2003252178A1 (en) 2002-07-25 2004-02-16 Advances Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
JP2006510657A (ja) 2002-12-06 2006-03-30 アライバ ファーマシューティカルズ，インコーポレイティド 中耳炎の処置のための方法および組成物
US20040220242A1 (en) 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
JP2007504144A (ja) 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
PL1694342T3 (pl) 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
EP2335722B1 (en) 2004-05-12 2019-03-13 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat infections
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
EP1909810B2 (en) * 2005-06-07 2017-08-23 The Regents of the University of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US20090227518A1 (en) 2005-12-02 2009-09-10 The Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
EP2148693A4 (en) 2007-04-20 2010-06-02 Univ Colorado ALPHA-I-ANTITRYPINE WITHOUT SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2423233B1 (en) 2009-04-22 2015-03-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011156820A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for treatment of type 1 diabetes
US9938353B2 (en) * 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
IN2013MN02442A (OSRAM) 2011-06-28 2015-06-12 Inhibrx Llc
PT2726092T (pt) * 2011-06-28 2019-10-08 Lp Inhibrx Polipéptidos de fusão serpina e métodos para a sua utilização
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017079769A (ja) * 2011-06-24 2017-05-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Also Published As

Publication number Publication date
US20200109215A1 (en) 2020-04-09
AU2018200571C1 (en) 2020-04-23
AU2016202734A1 (en) 2016-05-19
US20180208681A1 (en) 2018-07-26
US20250101131A1 (en) 2025-03-27
KR20200044138A (ko) 2020-04-28
AU2018200571A1 (en) 2018-02-15
US20220204646A1 (en) 2022-06-30
EP3628327A1 (en) 2020-04-01
JP2014519852A (ja) 2014-08-21
AU2019257412A1 (en) 2019-11-14
JP2019058197A (ja) 2019-04-18
WO2012178102A2 (en) 2012-12-27
US9938353B2 (en) 2018-04-10
KR102103476B1 (ko) 2020-04-23
JP2017079769A (ja) 2017-05-18
AU2019257412B2 (en) 2022-01-06
JP2020171316A (ja) 2020-10-22
EP2723370A2 (en) 2014-04-30
AU2018200571B2 (en) 2019-11-21
CA2839917A1 (en) 2012-12-27
EP2723370A4 (en) 2015-06-03
US12030958B2 (en) 2024-07-09
WO2012178102A3 (en) 2013-03-28
US10450384B2 (en) 2019-10-22
AU2012272636A1 (en) 2013-05-02
US20140341899A1 (en) 2014-11-20
KR20140096257A (ko) 2014-08-05

Similar Documents

Publication Publication Date Title
JP6216921B2 (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP6920230B2 (ja) アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物
JP7489111B2 (ja) 非ペプチジル結合を含むハイブリッド免疫グロブリン
EP2109457B1 (en) Therapeutic application of kazal-type serine protease inhibitors
AU2021225156B2 (en) UTI fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170628

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170727

R150 Certificate of patent or registration of utility model

Ref document number: 6216921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees